Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Trial Design Challenge: Does Same Indication Demand Same Kind Of Study?

Executive Summary

Luitpold citizen petition seeking to block AMAG’s expanded indication for injectable iron offers FDA an opportunity to weigh in on how similar trial designs must be for drugs with the same indication.

You may also be interested in...

AMAG’s Turnaround Plans Hit A Snag With Feraheme CRL

FDA declined to approve the I.V. iron in a broad patient population and requested another clinical trial to further evaluate safety. The decision gives rival Daiichi more time to penetrate the market with its I.V. iron Injectafer.

AMAG’s Feraheme Expansion Strategy Delayed For Now

FDA has extended by three months its review of a sNDA for the I.V. iron product that would expand the drug’s use into a far broader patient population.

Luitpold Citizen Petition May Handicap AMAG’s Ferumoxytol

A citizen petition filed by AMAG rival Luitpold stressing the dangers of intravenous iron therapy - an area with well-known hazards - seems designed to handicap AMAG's nanoparticle agent ferumoxytol, which bears a PDUFA date of Oct. 19


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts